Published in J Clin Microbiol on April 15, 2015
ve-SEQ: Robust, unbiased enrichment for streamlined detection and whole-genome sequencing of HCV and other highly diverse pathogens. F1000Res (2015) 1.02
A method for near full-length amplification and sequencing for six hepatitis C virus genotypes. BMC Genomics (2016) 0.86
Sequencing Analysis of NS3/4A, NS5A, and NS5B Genes from Patients Infected with Hepatitis C Virus Genotypes 5 and 6. J Clin Microbiol (2016) 0.75
A Complex Network of Interactions between S282 and G283 of Hepatitis C Virus Nonstructural Protein 5B and the Template Strand Affects Susceptibility to Sofosbuvir and Ribavirin. Antimicrob Agents Chemother (2016) 0.75
Next-Generation Sequencing: a Diagnostic One-Stop Shop for Hepatitis C? J Clin Microbiol (2016) 0.75
MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol (2011) 220.97
Clustal W and Clustal X version 2.0. Bioinformatics (2007) 126.47
A greedy algorithm for aligning DNA sequences. J Comput Biol (2000) 47.89
Genetic diversity and evolution of hepatitis C virus--15 years on. J Gen Virol (2004) 6.67
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med (2013) 6.08
Full-length sequence of a hepatitis C virus genome having poor homology to reported isolates: comparative study of four distinct genotypes. Virology (1992) 5.16
Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology (2014) 4.15
A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg. J Virol (2002) 3.20
Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5' untranslated region sequences. J Clin Microbiol (2007) 2.55
Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin. Hepatology (2014) 2.27
The origin of hepatitis C virus genotypes. J Gen Virol (1997) 2.26
Complete viral RNA genome sequencing of ultra-low copy samples by sequence-independent amplification. Nucleic Acids Res (2012) 2.19
MOSAIK: a hash-based algorithm for accurate next-generation sequencing short-read mapping. PLoS One (2014) 2.12
Novel isothermal, linear nucleic acid amplification systems for highly multiplexed applications. Clin Chem (2005) 2.10
De novo assembly of highly diverse viral populations. BMC Genomics (2012) 1.87
The mode and tempo of hepatitis C virus evolution within and among hosts. BMC Evol Biol (2011) 1.46
Analysis of hepatitis C virus intrahost diversity across the coding region by ultradeep pyrosequencing. J Virol (2012) 1.29
Full-length complementary DNA of hepatitis C virus genome from an infectious blood sample. Hepatology (1998) 1.26
Use of illumina deep sequencing technology to differentiate hepatitis C virus variants. J Clin Microbiol (2012) 1.19
NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5. Antivir Ther (2011) 1.16
Genetic recombination of the hepatitis C virus: clinical implications. J Viral Hepat (2010) 1.09
Whole genome pyrosequencing of rare hepatitis C virus genotypes enhances subtype classification and identification of naturally occurring drug resistance variants. J Infect Dis (2012) 0.94
Full-length genome sequences of hepatitis C virus subtype 4f. J Gen Virol (2007) 0.86
Antigenic heterogeneity of the hepatitis C virus NS5A protein. J Clin Microbiol (2002) 0.78
The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro. Antimicrob Agents Chemother (2014) 0.84
Reduced viral fitness and lack of cross-class resistance with integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutations. Antimicrob Agents Chemother (2015) 0.78
Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions. Antimicrob Agents Chemother (2015) 0.77
Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus. J Gastroenterol Hepatol (2016) 0.76
A Complex Network of Interactions between S282 and G283 of Hepatitis C Virus Nonstructural Protein 5B and the Template Strand Affects Susceptibility to Sofosbuvir and Ribavirin. Antimicrob Agents Chemother (2016) 0.75
A cell-based strategy to assess intrinsic inhibition efficiencies of HIV-1 reverse transcriptase inhibitors. Antimicrob Agents Chemother (2014) 0.75
Identification of Hepatitis C Virus 2k/1b Intergenotypic Recombinants in Georgia. Liver Int (2017) 0.75
In vitro anti-hepatitis C virus (HCV) resistance selection and characterization. Curr Protoc Pharmacol (2011) 0.75
Resistance Analysis in Patients with Genotype 1-6 HCV Infection Treated with Sofosbuvir/Velpatasvir in the Phase 3 Studies. J Hepatol (2017) 0.75